Literature DB >> 1718889

Inhibition of antigen-induced late asthmatic response and bronchial hyperresponsiveness by cyclosporin and FK 506.

T Fukuda1, I Akutsu, S Motojima, S Makino.   

Abstract

Using a guinea pig model of asthma, we have shown that the administration of cyclosporin, a T-lymphocyte-selective immunosuppressive agent, from the beginning of the immunization period inhibits the development of the late asthmatic response and bronchial hyperresponsiveness after antigen challenge. Similar results were obtained with FK 506, a new potent immunosuppressive agent. Since these compounds have been shown to suppress the activation of guinea pig T lymphocytes, the present data suggest that T lymphocytes may be important for the elicitation of the late asthmatic response and bronchial hyperresponsiveness.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1718889     DOI: 10.1159/000235377

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  5 in total

Review 1.  Immunosuppressive agents and asthma.

Authors:  T Fukuda
Journal:  Clin Rev Allergy       Date:  1994

2.  Parainfluenza virus type-3 infection attenuates the respiratory effects of antigen challenge in sensitized guinea pigs.

Authors:  E M Kudlacz; R W Knippenberg
Journal:  Inflamm Res       Date:  1995-03       Impact factor: 4.575

3.  Inhibition by rapamycin of leukocyte migration and bronchial hyperreactivity induced by injection of Sephadex beads to guinea-pigs.

Authors:  J Nogueira de Francischi; D M Conroy; K Maghni; P Sirois
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

4.  Effects of dexamethasone and cyclosporin A on the accumulation of eosinophils in acute cutaneous inflammation in the guinea-pig.

Authors:  M M Teixeira; T J Williams; P G Hellewell
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

Review 5.  The regulation of pulmonary immunity.

Authors:  M F Lipscomb; D E Bice; C R Lyons; M R Schuyler; D Wilkes
Journal:  Adv Immunol       Date:  1995       Impact factor: 3.543

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.